MedTrace Logo

Expanded Access Protocol of ELI-002-102 in Subjects With KRAS/NRAS Mutated Pancreatic Ductal Adenocarcinoma

NCT07083479 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2026-05-19

No results posted yet for this study

Summary

This is an open-label expanded access protocol (EAP) of ELI-002 7P immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide \[Amph-CpG-7909\] plus a mixture of lipid-conjugated peptide-based antigens \[Amph-Peptides 7P\]) as adjuvant treatment in patients with KRAS/NRAS-mutated pancreatic ductal adenocarcinoma who are at high risk for relapse (ie, presence of isolated tumor cells in a patient whose primary tumor has been removed and is currently without clinical signs of disease). This protocol builds on the experience being obtained with ELI-002 7P (with Amph-Peptides G12D, G12R, G12V, G12A, G12C, G12S, G13D), which is being studied in protocol ELI-002-201.

Conditions

  • Pancreatic Ductal Adenocarcinoma
  • KRAS G12D
  • KRAS G12V
  • KRAS G12S
  • KRAS G12A
  • KRAS G12C
  • KRAS G12R
  • KRAS G13D
  • NRAS G12D
  • NRAS G12V
  • NRAS G12S
  • NRAS G12A
  • NRAS G12C
  • NRAS G12R
  • NRAS G13D

Interventions

DRUG

ELI-002 7P

ELI-002 Amph-CpG-7909 (10.0 mg) admixed with ELI-002 Amph-Peptides 7P (4.9 mg) administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization Period; additional SC injections weekly for 4 weeks during the Booster Period (the two periods are separated by 2 months of no dosing).

Sponsors & Collaborators

  • Elicio Therapeutics

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07083479 on ClinicalTrials.gov